Development of oral taurine therapy for the treatment of stroke-like epiodes of MELAS

Development of oral taurine therapy for the treatment of stroke-like epiodes of MELAS - Taurine therapy for stroke-like epiodes of MELAS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005592

Enrollment

Registered

2011-05-12

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MELAS

Interventions

Twelve patients with MELAS having A3243G and T3271C mutations in the mitochondrial DNA are enrolled in the study. Oral taurine (12 g/d&gt

BW40 kg

9 g/d:25-39 kg

6 g/d:15-24 kg

3 g/d&lt

15 kg) is administered to the patients for 24 months to evaluate the efficacy of the prevention for stroke-like episodes.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male and female patients

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
-Frequency of stroke-like episodes -Score of neurological disability -Degree of brain MRI lesions	—

Countries

Japan

Contacts

Public ContactYutaka Ohsawa

Kawasaki Medical School Neurology

yosawa@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026